Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (December 2023)
37 slides from Genelux's investor presentation, Dec 12, 2023
Slide 1: Redefining Immuno-Oncology: Corporate Presentation December 2023
@eNELUXx Redefining Immuno-Oncology Corporate Presentation December 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Ge
Slide 3: Highlights
Highlights Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICE™ Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes eS Validating
Slide 4: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: 7 Completed Clinical Trials (>150 Patients) Physician-preferred Routes Antitumor Effect Ideal Backbone of of Delivery and Well Tolerated Combination Therapy © Regional and systemic administration to © Strong data in Phase 1b/2 st
Slide 5: Program Builds on Completed Trials to Exploit Competitive Advantages
Program Builds on Completed Trials to Exploit Competitive Advantages Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (US) Olvi-Vec Human Health Design Preclinical Phase1 © Phase2 — Phase 3 Notes | Collaborators Topline results 7 varan Concer Olvivec fipe) + Ph3 OnPrime/GOG-2076
Slide 6: Selective Replication In Tumors Unleashes Immune System Against Cancer
Selective Replication In Tumors Unleashes Immune System Against Cancer Key Takeaways IN Innate Adaptive Olvi-Vec Immune Activation Immune Activation viral infection Olvi-Vec is a robust immune Genes sncrease Type = ancepresent (nolan modulator that utilizes a triple ee eee ee itattee «‘Teelnavaton e
Slide 7: Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance
Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance Olvi-Vec-Induced Hot Tumor Chemotherapy synergy Pro-therapeutic gene expression > Positive regulation of T-cell activating Memanesenic cell death and trafficking > Depletion of suppressor cells > Increase susceptibility to cytotoxic T- l
Slide 8: A Maturing Modality with Phase Companies validating OV Potential
A Maturing Modality with Phase 3 Companies validating OV Potential ENELUX > Next Generation Phase 2 Ovarian Cancer Phase 1b Solid Tumors Limitations of 1s Gen Viruses + Commercial/Late-stage 1 Generation viruses confirm modality's potential + limited to local delivery and scope of addressable cancer
Slide 9: Phase 1b: Anti-tumor Activity as Monotherapy
hase 1b: Anti-tumor Activity as Monothera Leading into Combination Key Clinical Takeaways IN + mPFS of 6.1 months (median 4 prior lines; 95%CI: 2.2-NA) for the six patients in Cohort 1 virus monotherapy — the dose used in Phase 2. 1. SOC-AURELIA regimen (1-2 ~ MPFS: 5.62 mos + Cohort 2/3 dosing done
Slide 10: Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy Heavily Pretreated Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer Data Presentations n=27 Gynecologic Cancer Society Oral Plenary Session + High-grade serous, endometri Resin 2. JAMA Oncology Olvi-Vec via intraperito
Slide 11: Clinically Meaningful Responses in Heavily Pretreated Patients
Phase 2 Clinically Meaningful Responses in Heavily Pretreated Patients IN Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC Key Clinical Takeaways + All patients had documented progressive disease at enrollment + The median PFS of the pa
Slide 12: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage IN Refractory patients performed as well as resistant patients Key Clinical Takeaways * Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction + Four patients had 100% reduction of target l
Slide 13: Olvi-Vec-Primed Immunochemotherapy Overcomes Refractoriness
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness' Exemplary platinum-refractory patients, after platinum re-challenge, 15B-01; ‘Stage IIB papillary serous ECOG: 0 BRCA negative PD-Li negative achieved PFS exceeding any prior lines 1SB-15: + Stage IIIB high- grade serous + £COG:0 + BRCA n
Slide 14: Durable Survival Benefit
Durable Survival Benefit Prognosis Worsens with each Successive Line Tistorical Data? ELAHARE? » Paine AAMOS BRC TPM TO Key Clinical Takeaways 10 -| 3Tine __12.9m0s (95% Cl, 10.4-14.6) | 187 MOS 2/3") @line 98 mOS (95% C,7.4-12.25) | 116 m0S Tline Not reported N/A. Encouraging mos and 084 SSORAAPS W
Slide 15: All-comers Approach May Reset Life Clock of Heavily Pre-treated Patients
“Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients While clinical remissions are obtainable, a majority of patients will relapse. » Genelux looks to take an all-comers approach Key Clinical Takeaways _ asm 80% L 7% | Olvi-Vec addresses a broad oom 4) and underserved pool of 40
Slide 16: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment Key Inclusion Criteri: Multi-center, randomized open-label =186 + High-grad
Slide 17: Systemic administration demonstrated dose-dependent OS benefit
S) stemic administration demonstrated dose-dependent OS benefit Key Clinical Takeaways Demonstrated feasibility and clinical benefit of multiple IV cycles + Median 5 prior lines of therapy * Regimen: various dosing levels and schedules (typically over 4-6 months) + Well tolerated: no-MTD reached wit
Slide 18: Systemic Administration + Chemo Generated Encouraging Data
stemic Administration + Chemo Generated Encouraging Data ncer , AdventHenith | rancst, : Expanded Access Program Key Clinical Takeaways Recurrent metastatic cervical cancer | High-grade pancreatic cancer with with lung mets lung & liver mets 4 Report (LIAO) case Report (3214-04) Andl=tumor.effect ot
Slide 19: Genelux has Partnered with Newsoara BioPharma Co., Ltd
Genelux has Partnered with Newsoara BioPharma Co., Ltd JENELUX Benny Li, PhD Founder and Chief Executive Officer 20+ yrs. global and China local pharma Former VP, GM of Takeda China Development Center and SVP, Executive GM of R&D at Hansoh Pharmaceuticals Former Head of Clinical Development & Medica
Slide 20: Validating Industry Collaboration with Newsoara BioPharma Co., Ltd
Validating Industry Collaboration with Newsoara BioPharma Co., Ltd Key Takeaways » * Newsoara will fund the US- based Genelux Phase 2 trial in NSCLC + Newsoara has development and commercialization rights in Greater China » Systemic Trial Milestones + Initiate Phase 2 NSCLC: 1H, 2024 * Phase Ib SCLC
Slide 21: V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical Key Trial Takeaways » V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy + Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunost
Slide 22: Self Launch Olvi-Vec for Ovarian Cancer in the US
Self Launch Olvi-Vec for Ovarian Cancer in the US (sy (=>) © a © Partnerships Self-Manufacturing Patients Reimbursement Leverage partnership Large-Scale cGMP Underappreciated Compelling Value with GOG Foundation Manufacturing Population Proposition for Payors Preeminent US-based Control of Productio
Slide 23: Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch
Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Key Takeaways » Facilities and Operations based in Southern California eli Hace arieTe a GMP Manufact ig + Large-scale manufacturing, rocess + Capacity for clinical studies and commercial launch needs Translational Research * Clini
Slide 24: Choice Platform Library: 500+ Vectors with 110+ Transgenes
Choice Platform Library: 500+ Vectors with 110+ Transgenes Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes Therapeutic ) Cell Growth & Differentiation Regulators Hormones Genes Metastasis Suppressor Gene
Slide 25: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate | Patent Portfolio: 33 issued patents; 7 pending + Olvi-Vec covered by Composition of Matter (2031) and Manufacturing (2038) St ng IP & “~~ Olvi-Vec: Worldwide operating freedom; Regulatory No third-party royalties due Designations CO Lo
Slide 26: Accomplished Leadership Team
Accomplished Leadership Team Executive Team Board of Directors THOMAS ZINDRICK JO waey serornics Chairman of he Board DNX aici Myer suites JAMES L. TYREE, MBA 2 Lead Independent director fer anos Thomas Zindrick, JD Lourie Zak Paul Scigalla, MD, PhD ‘Sean Ryder, JD hf Chiet Executive officer Chiet F
Slide 27: Expected Operating Runway into 2Q 2025
Expected Operating Runway into 2Q 2025 Capitalization Summary Stock Symbol GNLX Share Price) $12.84 Shares Outstanding 26.7M Market Capitalization" $328.3M Cash & Equivalents?) §29.9M PIPE Commitments Due $ 2M” Insider Ownership ruuy owuteo 25.4% Analyst Coverage + Kemp Dolliver CFA + Emily Bodner H
Slide 28: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Executed Milestones IN NANA Executed on go public strategy _—-®-— and follow on with $60M raised . — 2H, 2025 Initiation of Phase 3 Trial in ( } 2H, 2024 Topline readout in PRROC PRROC Interim readout in phase 3 registratio
Slide 29: Highlights
Highlights Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICE™ Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes EY Validating
Slide 30: Appendix
@eNELUXx Redefining Immuno-Oncology Corporate Presentation | December 2023 Appendix
Slide 31: Accomplished Clinical Advisory Board
lished Clinical Advisory Board Accom Tresor Robert Holloway, MD encase CHAIRMAN Scena Robert Coleman, MD Member o-brecer eee Albert A. Mendivil, MD “vein Member eet Thomas J. Herzog, MD cna Chief Executive Officer rotator and ones David M. O'Malley, MD morse Chief Medical Officer Concern Alan Forsyt
Slide 32: Olvi-Vec-primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker
Olvi-Vec-primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker Rapid, Common and Durable Responses (A-125 Decrease ORR by CA-125 © All PRROC Patients: 96% (25/26) © All PRROC Patients: 85% (22/26) © Platinum refractory patients: 85% (11/13) o Platinum refractory patients: 85% (11/13) x SF
Slide 33: Olvi-Vec-Primed Immunochemotherapy Overcomes Refractoriness
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 158.15: t.15B-45 (primary platinum-refractory HGSOC) © stage lbh grade serous 1 son + fc0G:0 J start chemo/sevaczumab + BRCA negat
Slide 34: Olvi-Vec Monotherapy Demonstrates Oncolysis and Immune Activation
Olvi-Vec Monotherapy Demonstrates Oncolysis and Immune Activation p (1RO-15: monotherapy) Key Takeaways (Pt.#15A-01) (Pt#15A-11) Elimination of Cancer Cells after Increased Lymphocyte Infiltration in different cavities peritoneal fluid pleural fluid Prior 01 dove Olvi-Vec monotherapy shows decreased
Slide 35: CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival
CD8+ T-cells: infiltrating Lymphocytes are Prognostic for Response/Survival Pt# 15A-16 Pt# 15A-18 Pt# 45A-23 ~ Le BS ad sc Soe coa+ cas co4+ coB+ an om Post-Olvi-Vee (prior to subsequent chemotherapy) Endogenous Tis (intra- tumoral and stromal) are very low in ovarian cancer Pt# 15A-16 Pt# 15A-18 42
Slide 36: Long-lasting, Tumor-specific T cell response corresponds to tumor reduction
Long-lasting, Tumor-specific T cell response corresponds to tumor reduction (W015: nonotherapy a Contin tavorantigen presentation Case Report (Pt #15A-05) = '& immune setivationimemory IN Heavily pre-treated: se | ex) Key Takeaways 9 prior regimens of chemot Avastin; | “usrea=* no pre-existing tumor
Slide 37: Olvi-Vec: Ideal Backbone for Combination Therapy
Olvi-Vec: Ideal Backbone for Combination Thera Converts Tumor Microenvironment to Inflammatory “Hot Spot” NCT01443260/TUE Study 4 Induction of acute inflammatory cytokines (Thi-type related) Fold-change from Baseline VIRO-15 Study Baseline Massive inflammatory response after cycle 1 of ius treatment